Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients
Article Abstract:
Monoclonal antibodies against bacterial toxins may be cost-effective in treating patients with gram-negative bacterial infections, provided the patient is not in septic shock. Even though these antibodies are expensive - with an estimated cost of $2,000 to $4,000 - they have been shown to increase survival, and non-survivors use more resources in intensive care units than survivors. A model based on clinical studies of monoclonal antibodies in gram-negative infections included the estimated cost of the antibodies to determine the cost-effectiveness of the treatment. Use of monoclonal antibodies was found to have a lower cost-effectiveness ratio than standard antibiotic treatment because the antibodies reduced mortality slightly. Monoclonal antibodies would be less cost-effective than antibiotics only if their cost exceeded $5,000.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1993
User Contributions:
Comment about this article or add new information about this topic:
Immune-Based, Targeted Therapy for Allergic Diseases
Article Abstract:
A monoclonal antibody called omalizumab may be effective in treating hay-fever and preventing asthma. This drug blocks immunoglobulin E (IgE), which is produced in excessive levels in patients with hay-fever. It may also increase the risk of developing asthma in patients with chronic hay-fever.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Monoclonal Antibody Therapy in the Treatment of Non-Hodgkin Lymphoma
Article Abstract:
Researchers are developing monoclonal antibodies that can be used to treat non-Hodgkin's lymphoma. Monoclonal antibodies are antibodies against a specific protein, which in the case of non-Hodgkin's lymphoma, is the CD20 protein on the surface of abnormal B cells.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Monoclonal antibodies for gram-negative sepsis. Rituximab for non-Hodgkins lymphoma. Gemtuzumab for relapsed acute myeloid leukemia
- Abstracts: A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania. Pediatric Obsessive-Compulsive Disorder
- Abstracts: Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Comparison of two forms of the anticlotting drug heparin for treatment of blood clots in the legs
- Abstracts: Prevalence of antibodies to glutamic acid decarboxylase in women who have had gestational diabetes. The effect of vascular coiling on venous perfusion during experimental umbilical cord encirclement
- Abstracts: Effects of aging and gonadal failure on the hypothalamic-pituitary axis in women. The lack of influence of age on male fertility